

## Curriculum Vitae

### PERSONAL INFORMATION

Family name, first name, title(s): **Rázga, Filip, Chem. Eng., PhD.**  
Address: Sokolská 15, 903 01 Senec, Slovak Republic  
Telephone: +421 903 031 518  
e-mail: [filip.razga@savba.sk](mailto:filip.razga@savba.sk)  
Date of birth: 31.05.1979  
Gender: Male

### EDUCATION

2013 **Scientific degree II.a** (equivalent to Associate Professor)  
Slovak Academy of Sciences, Bratislava, Slovak Republic

2007 **PhD.**  
Biomolecular chemistry  
Faculty of Sciences, Masaryk University Brno, National Centre for Biomolecular Research,  
Brno, Czech Republic

2002 **Chemical Engineer** (Master of Science)  
Physical chemistry  
Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava,  
Bratislava, Slovak Republic

### PROFESSIONAL TRAINING

2012 Completion of specialized training (Institute of postgraduate education – „IPE“): Molecular  
genetical diagnostics in clinical practice

Completion of specialized training – IPE: Generic module for study programs clinical  
biochemistry, alergology and clinical immunology, clinical genetics, nuclear medicine

Completion of specialized training – IPE: MIPREM module for study programs clinical  
biochemistry, alergology and clinical immunology, clinical genetics, nuclear medicine

Completion of specialized training – IPE: ANAL module for study programs clinical  
biochemistry, alergology and clinical immunology, clinical genetics, nuclear medicine

Completion of specialized training – IPE: Advances in medical genetics

Completion of specialized internship: Cytogenetics

Completion of specialized internship: Molecular genetics

Completion of specialized internship: Clinical biochemistry

Completion of specialized internship: Clinical microbiology

Completion of specialized internship: Genetics

2011 Enrollment to specialized training: Clinical genetics

2010 Certificate – IPE: Professional in medical laboratory methods

2009 Completion of specialized training – IPE: Basics of healthcare legislation

Completion of specialized training – IPE: Starting medical module

Completion of specialized training – IPE: General work principles in medical laboratories

Completion of specialized training – IPE: First aid

## **WORKING POSITION(S)**

2013 -	<b>Research Scientist</b> Polymer Institute of the Slovak Academy of Sciences (PISAS), Bratislava, Slovak Republic
2010-2013	<b>External Research Scientist</b> Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic
2008-2013	<b>Research Scientist – Specialist in laboratory methods and drug preparation</b> Department of Internal Hematology and Oncology, Faculty Hospital Brno, Brno, Czech Republic
2005-2007	<b>Research Assistant</b> National Centre for Biomolecular Research, Masaryk University Brno, Brno, Czech Republic  Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic

## **AWARDS**

2015	Award of the Slovak Academy of Sciences, for science popularization
2008	Award of the Ministry of Education, Youth and Sports of the Czech Republic, for excellent graduates of the study program, for outstanding achievements in study and creative activities in the field of Biomolecular chemistry  Award of the Rector of the Masaryk University Brno, Czech Republic, for excellent PhD thesis at the Faculty of Sciences
2007	Award of Institute of Biophysics of the Academy of Sciences of the Czech Republic, Brno, Czech Republic, for outstanding scientific work
2006	Award of the Dean of Faculty of Sciences, Masaryk University Brno, Czech Republic, for academic excellence and success in creative work and research in the field of Physical chemistry

## **SUPERVISION OF GRADUATE STUDENTS**

2016	1/Bc student (co-supervision) Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava, Bratislava, Slovak Republic
2015-	1/PhD student Polymer Institute of the Slovak Academy of Sciences, Bratislava, Slovak Republic
2014-	1/PhD student Polymer Institute of the Slovak Academy of Sciences, Bratislava, Slovak Republic
2012-2014	1/Master student Faculty of Sciences, Department of Molecular Biology and Genetics, Masaryk University Brno, Brno, Czech Republic
2013-2015	1/PhD student (co-supervision) Polymer Institute of the Slovak Academy of Sciences, Bratislava, Slovak Republic

## **TEACHING ACTIVITIES**

2011-2013	Seminar tutor (4 semesters, 4 hrs/month): Internal medicine/Clinical examination in internal medicine, Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic
-----------	---

## **MEMBERSHIP OF SCIENTIFIC SOCIETIES**

2014-	Scientific Council – Polymer Institute of the Slovak Academy of Sciences
2012-	CELL – The Czech leukemia study group for life

## GRANTS

Project Title	Funding source	Amount (€)	Period	PI*	Relation to current SASPRO proposal
New generation PMCG multicomponent microcapsule with tailored biointerface to avoid immune response after transplantation	JDRF	700,000	2017-2020	No	No
Gold nanoparticles: impact of physicochemical properties on distribution, accumulation, and biological response <i>in vivo</i>	Slovak research and development agency	180,000	2017-2021	No	No
Multivalent morpholino-based antisense system for CML	Slovak research and development agency	249,999	2016-2020	Yes	Yes
Materials and processes for functional encapsulation of pancreatic islets in diabetes treatment	Slovak research and development agency	245,922	2015-2019	No	No
Conjugated antisense system for selective and specific BCR-ABL suppression: An innovative strategy for CML treatment	SASPRO	206,823	2015-2017	Yes	Yes
Mechanisms of gold and magnetite nanoparticles effects on renal cells	Ministry of Education, Science, Research and Sport of the Slovak Republic	31,696	2015-2018	No	No
Modeling and synthesis of hybrid conjugated systems for anticancer therapy	Ministry of Education, Science, Research and Sport of the Slovak Republic	19,908	2015-2018	Yes	Yes
Multicomponent microcapsules for allogeneic islet transplantation in a comprehensive, preclinical non-human primate model	JDRF	603,000	2014-2016	No	No
Morpholino - a unique antisense system for gene silencing: synthesis and oligomerization	PISAS	1,600	2014	Yes	Yes
Peptide modified hydrogels for the improvement of immune protection of encapsulated cells	Ministry of Education, Science, Research and Sport of the Slovak Republic	15,000	2012-2014	No	No
Kinetics and bio-applications of zwitterionic polymers	Ministry of Education, Science, Research and Sport of the Slovak Republic	33,000	2014-2016	No	No
Advanced polymer technologies in biomedicine: Polymer microcapsules for immunoprotection of transplanted pancreatic islets in diabetes treatment	Slovak research and development agency	249,000	2011-2014	No	No
Carbonic anhydrase IX as a functional component of cancer progression: the role in epithelial-mesenchymal transition and intercellular signaling	Slovak research and development agency	210,000	2012-2015	No	No
Expression of <i>hOCT-1</i> , <i>ABCB1</i> in different blood cells: a possible role of individual cell population in clinical resistance	Novartis	275,000	2009-2011	No	No
The hematopoietic microenvironment and the model of human physiological and malignant hematopoiesis	Novartis, BMS	51,000	2011-2013	No	No
Cepheid: automated system for <i>BCR-ABL1</i> monitoring	Ministry of Health of the Czech Republic, Faculty Hospital Brno	50,000	2013	No	No
Increase of quality and capacity of molecular diagnostics in the Dept. of Internal Hematology and Oncology, Faculty Hospital Brno	Novartis	41,000	2013	No	No

Analysis of CD34 + cells in patients with CML using next-generation sequencing	Novartis	39,000	2013	No	No
--	----------	--------	------	----	----

\* Yes - Principal investigator; No - Member

## LIST OF PUBLICATIONS

- **10 selected publications out of 45 total publications are described briefly**
- **these publications were prepared without the presence of PhD supervisor as co-author**
- **Filip Razga is in all these publications either the first, equally contributing or corresponding author**

Mazancova P, Nemethova V, Trelova D, Klescikova L, Lacik I, **Razga F**. Disintegration of chitosan/tripolyphosphate complexes into separate components upon pH elevation. **2017**, *Biomaterials*, [submitted](#)

**Razga F**, Nemethova V. Selective therapeutic intervention: A challenge against off-target effects. **2017**, *Trends Mol Med*; 23: 671-4, IF: 10.73

Nemethova V, **Razga F**. CML on target. **2017**, *Critical Reviews in Hematology/Oncology*, [submitted](#)

Mazancova P, Nemethova V, Lacik I, **Razga F**. Chitosan-based particles: The (forgotten) interplay between process, properties and performance. **2017**, *Mater Sci Eng C*; 71: 570-1, IF: 3.42

**Razga F**, Nemethova V. Gene expression patterns as predictive biomarkers in hemato-oncology: principal hurdles on the road to the clinic. **2017**, *Haematologica*; 102(1): e31-2, IF: 6.67

Nemethova V, **Razga F**. Overexpression of *ABCB1* as prediction marker for CML: How close we are to translation into clinics? **2017**, *Leukemia*; 31(1): 266-7. IF: 12.10

Nemethova V, Bulikova B, Mazancova P, Babelova A, Selc M, Moravcikova D, Klescikova L, Ursinyova M, Gabelova A, **Razga F**. Intracellular uptake of magnetite nanoparticles: a focus on physico-chemical characterization and interpretation of *in vitro* data. **2017**, *Mater Sci Eng C*; 70: 161-8, IF: 3.42

**Razga F**, Vnukova D, Nemethova V, Mazancova P, Lacik I. Preparation of chitosan-TPP sub-micron particles: Critical evaluation and derived recommendations. **2016**, *Carbohydr Polym*; 151: 488-99, IF: 4.07

Musilova M, **Razga F**, Jurcek T, Jeziskova I, Borsky M, Nemethova V, Dvorakova D, Mayer J, Racil Z., BCR-ABL1 Kinase domain mutational analysis of CD34+ stem/progenitor cells by Next-generation sequencing. **2014**. *Am J Hematol*; 89(10):1016-7, IF: 4.00

Racil Z, **Razga F**, Drapalova J, Buresova L, Zackova D, Palackova M, Semerad L, Malaskova L, Haluzik M, Mayer J. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. **2013**. *Haematologica*, 98(10): e124-6, IF: 5.94

- **Other publications where Filip Razga is either the first author, equally contributing or corresponding author**

Nemethova V, Lacik I, **Razga F**. Vibration Technology for Cell Encapsulation: Viscosity as the Achilles' Heel. **2017**, *Chem Pap*; 71(9): 1563-7, IF: 1.26

Nemethova V, Lacik I, **Razga F**. Vibration technology for microencapsulation: The restrictive role of viscosity. **2015**, *J Bioprocess Biotech*; 5(1): 199-201, IF: 2.55

Racil Z, **Razga F**, Klamova H, Voglova J, Belohlavkova P, Malaskova L, Potesil D, Muzik J, Zackova D, Polakova KM, Zdrahal Z, Malakova J, Suttar J, Dyr J, Mayer J. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia. **2014**. *Hematol Oncol*; 32(2): 87-93, IF:2.04

Jurcek T, **Razga F**, Mazancova P, Musilova M, Dvorakova D, Borsky M, Zackova D, Dobesova B, Semerad L, Mayer J, Racil Z. The prospective analysis of low-level BCR-ABL1 T315I mutation in the CD34+ cells of de novo CML patients. **2014**. *Leuk Lymphoma*; 55(8):1915-7, IF: 2.40

Jeziskova I, **Razga F**, Toskova M, Dvorakova D, Timilsina S, Mayer J, Racil Z. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene. **2013**. *Leuk Lymphoma*, 54(4): 867-70, IF: 2.40

Malcikova J, **Razga F**, Jurcek T, Dvorakova D, Zackova D, Toskova M, Sebejova L, Smardova J, Oltova A, Vankova G, Jurackova L, Trbusek M, Pospisilova S, Mayer J, Racil Z. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitor therapy. **2013**. *Leuk Lymphoma*, 54(9): 2083-7, IF: 2.40

**Razga F**, Jurcek T, Jeziskova I, Zackova D, Dvorakova D, Borsky M, Mayer J, Racil Z. Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood. **2012**. *Mol Diagn Ther*; 16(3): 163-6, IF: 1.69

**Razga F**, Jurcek T, Zackova D, Dvorakova D, Toskova M, Jeziskova I, Mayer J, Racil Z. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations. **2012**. *Mol Diagn Ther*; 16(4): 251-9, IF: 1.69

**Razga F**, Racil Z, Machova Polakova K, Buresova L, Klamova H, Zackova D, Dvorakova D, Polivkova V, Cetkovsky P, Mayer J. The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. **2011**. *Int J Hematol*; 94(3): 303-6, IF: 1.17

Racil Z, **Razga F**, Polakova KM, Buresova L, Polivkova V, Dvorakova D, Zackova D, Klamova H, Cetkovsky P, Mayer J. Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types. **2011**. *Leuk Lymphoma*; 52(2): 331-4, IF: 2.40

Jezisková I, **Rázga F**, Gazdová J, Doubek M, Jurcek T, Korístek Z, Mayer J, Dvoráková D. A case of a novel PML/RARA short fusion transcript with truncated transcription variant 2 of the RARA gene. **2010**. *Mol Diagn Ther*; 14(2): 113-7, IF: 1.69

Racil Z, **Razga F**, Buresova L, Jurcek T, Dvorakova D, Zackova D, Timilsina S, Cetkovsky P, Mayer J. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. **2010**. *Am J Hematol*; 85(7): 525-8, IF: 4.00

Jeziskova I, **Razga F**, Bajerova M, Racil Z, Mayer J, Dvorakova D. IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status. **2010**. *Leuk Lymphoma*; 51(12): 2285-7, IF: 2.40

Jurcek T, **Razga F**, Jeziskova I, Dvorakova D, Zackova D, Tomasikova L, Oltova A, Mayer J. Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR-ABL transcript causing false-negative results by standard polymerase chain reaction. **2010**. *Leuk Lymphoma*; 51(3): 558-61, IF: 2.40

**Rázga F**, Dvoráková D, Jurcek T, Jezisková I, Krátková Z, Mayer J. CEBPA gene mutational status: a complete screening using high-resolution melt curve analysis. **2009**. *Mol Diagn Ther*; 13(3): 195-200, IF: 1.69

**Rázga F**, Koca J, Mokdad A, Sponer J. Elastic properties of ribosomal RNA building blocks: molecular dynamics of the GTPase-associated center rRNA. **2007**. *Nucleic Acids Res*; 35(12): 4007-17, IF: 8.28

**Rázga F**, Zacharias M, Réblová K, Koca J, Sponer J. RNA kink-turns as molecular elbows: hydration, cation binding, and large-scale dynamics. **2006**. *Structure*; 14(5): 825-35, IF: 5.99

**Rázga F**, Koca J, Sponer J, Leontis NB. Hinge-like motions in RNA kink-turns: the role of the second a-minor motif and nominally unpaired bases. **2005**. *Biophys J*; 88(5): 3466-85, IF: 3.67

**Rázga F**, Spackova N, Réblová K, Koca J, Leontis NB, Sponer J. Ribosomal RNA kink-turn motif--a flexible molecular hinge. **2004**. *J Biomol Struct Dyn*; 22(2): 183-94, IF: 4.99

#### - Publications where Filip Razga is co-author

Kronekova Z, Pelach M, Mazancova P, Uhelska L, Trelova D, Razga F, Nemethova V, Szalai Sz, Raus V, Chorvat D, McGarrigle JJ, Omami M, Isa D, Ghani S, Majkova E, Oberholzer J, Siffalovic P, Lacik I. Confocal Raman microscopy of hydrogel microspheres: environment-dependent spatial re-distribution of polymers and its consequences for *in vivo* studies. **2017**. *Scientific reports*, [submitted](#)

Buliakova B, Mesarosova M, Babelova A, Selc M, Nemethova V, Sebova L, **Razga F**, Ursinyova M, Chalupa I, Gabelova A. Surface-modified magnetite nanoparticles act as aneugen-like spindle poison. **2016**. *Nanomedicine: Nanotechnology, Biology, and Medicine*; 13(1): 69-82, IF: 6.16

Culen M, Borsky M, Nemethova V, **Razga F**, Smejkal J, Jurcek T, Dvorakova D, Zackova D, Weinbergerova B, Semerad L, Sadovnik I, Eisenwort G, Herrmann H, Valent P, Mayer J, Racil Z. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. **2016**. *Oncotarget*; 7(22): 33016-33024, IF: 6.35

Potesil D, Stejskal S, Borsky M, Simara P, Havelkova M, **Razga F**, Koutna I, Dvorakova D, Mayer J, Racil Z, Zdrahal Z. Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry. **2014**. Analytical Letters; 47(6): 944-957, IF: 0.95

Mesarosova M, Kozics K, Babelova A, Regendova E, Pastorek M, Vnukova D, Buliakova B, **Razga F**, Gabelova A. The role of reactive oxygen species in the genotoxicity of surface-modified magnetite nanoparticles. **2014**. Toxicol Lett; 226(3): 303-13, IF: 3.15

Zackova D, Klamova H, Muzik J, Cmunt E, Racil Z, Machova Polakova K, Dvorakova D, Jurcek T, **Razga F**, Cetkovsky P, Dusek L, Mayer J. Efficacy and Tolerance of Dasatinib after Imatinib Failure or Intolerance for Chronic Myeloid Leukemia Patients Treated in Three Different Hospitals Compare Well with Results Achievable in Formal Clinical Trials. **2013**. Leuk Lymphoma, 54(10): 2310-3, IF: 2.40

Dvorakova D, Racil Z, Borsky M, Robesova B, Jeziskova I, **Razga F**, Lengerova M, Mayer J. Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations. **2013**. Leuk Lymphoma, 54(5): 1056-60, IF: 2.40

Simara P, Peterkova M, Stejskal S, Potesilova M, Koutna I, Racil Z, **Razga F**, Jurcek T, Dvorakova D, Mayer J. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. **2012**. Leuk Lymphoma; 53(8): 1627-9, IF: 2.40

Racil Z, Toskova M, Dvorakova D, Jeziskova I, **Razga F**, Buresova L, Timilsina S, Mayer J. Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy. **2012**. Am J Hematol; 87(2): 211-3, IF: 4.00

Horky O, Mayer J, Kablaskova L, **Razga F**, Krejci M, Kissova J, Borsky M, Jeziskova I, Dvorakova D. Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse. **2011**. Int J Lab Hematol; 33(1): 57-66, IF: 1.30

Racil Z, Buresova L, Brejcha M, Prochazkova J, Zounar R, Timilsina S, **Razga F**, Toskova M, Cetkovsky P, Mayer J. Clinical and laboratory features of leukemias at the time of diagnosis: an analysis of 1,004 consecutive patients. **2011**. Am J Hematol; 86(9): 800-3, IF: 4.00

Zackova D, Klamova H, Dusek L, Muzik J, Polakova KM, Moravcova J, Jurcek T, Dvorakova D, Racil Z, Pospisil Z, Oltova A, Michalova K, Brezinova J, **Razga F**, Doubek M, Cetkovsky P, Trneny M, Mayer J. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? **2011**. Am J Hematol; 86(3): 318-21, IF: 4.00

Racil Z, Klamova H, Voglova J, Faber E, **Razga F**, Zackova D, Buresova L, Cetkovsky P, Mayer J. Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia. **2010**. Am J Hematol; 85(5): 386-9, IF: 4.00

Reblova K, **Razga F**, Li W, Gao H, Frank J, Sponer J. Dynamics of the base of ribosomal A-site finger revealed by molecular dynamics simulations and Cryo-EM. **2010**. Nucleic Acids Res; 38(4): 1325-40, IF: 8.28

Dvorakova D, Racil Z, Jeziskova I, Palasek I, Protivankova M, Lengerova M, **Razga F**, Mayer J. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations. **2010**. Am J Hematol; 85(12): 926-9, IF: 4.00

Reblova K, Lankas F, **Razga F**, Krasovska MV, Koca J, Sponer J. Structure, dynamics, and elasticity of free 16s rRNA helix 44 studied by molecular dynamics simulations. **2006**. Biopolymers; 82(5): 504-20, IF: 2.88

## **PARTICIPATION IN CONGRESSES/CONFERENCES**

### **- 4 selected conference proceedings in the last 5 years**

Jeziskova I, **Razga F**, Dvorakova D, Semerad L, Sustkova Z, Mayer J, Racil Z. Are mutations in the IDH2 gene suitable molecular markers for MRD monitoring in AML patients? 18th Congress of the European Hematology Association in Haematologica, **2013**. IF: 5.94

Racil Z, **Razga F**, Drapalova J, Buresova L, Zackova D, Palackova M, Semerad L, Malaskova L, Haluzik M, Mayer J. Mechanism of Impaired Glucose Metabolism during Nilotinib Therapy in Patients with Chronic Myelogenous Leukemia. 18th Congress of the European Hematology Association in Haematologica, **2013**. IF: 5.94

Borsky M, Nemethova V, **Razga F**, Mayer J, Racil Z. Surface antigen CD26 as a marker for purification of CML stem cells. Stem cells and cell therapy: from research to modern clinical application, **2013**.

Malcikova J, Jurcek T, **Razga F**, Dvorakova D, Zackova D, Darzentas N, Sebejova L, Smardova J, Oltova A, Jurackova L, Trbusek M, Doubek M, Pospisilova S, Mayer J, Racil Z. T315I mutations are clustered with advanced phases contrary to other aberrations in CML patients resistant to TKI therapy. 17th Congress of the European Hematology Association, Amsterdam, **2012**. IF: 5.94

## **SCIENTIFIC BOOK**

**Razga F**. Structure and dynamics of rRNA: A computational study, Scholars' Press, ISBN: 978-3-639-76604-2, eds. **2015**

## **TECHNOLOGY TRANSFER ACTIVITIES - PATENT(S)**

**Razga F**, Nemethova V. Immune-inertness: Morpholino-modified surfaces of materials for *in vivo* biomedical applications, filed 26/14 3.1, **in progress 2014**

**Razga F**, Nemethova V. Spôsob úpravy funkčného stavu ľubovolnej mRNA umožňujúci jej selektívne a špecifické rozpoznanie, filed PP50065-2015, C12N 15/00, **2017**

**Razga F**, Nemethova V. A method for altering the functional state of any mRNA allowing its selective and specific recognition, filed WO 2017/065696 A2, **2017**

Cervinka P, **Razga F**, Lacik I. Kvapkove delo, filed 131/16, **in progress 2017**

## **OUTREACH ACTIVITIES**

**Rázga F**. Cukrovka. Slobodný vysielateľ, Informačná vojna; 20.12.2013  
(<http://www.slobodnyvysielac.sk/redata/other/play.php?file=informacna%20vojna%20-%2020.12.2013.mp3>)

**Rázga F**, Lacik I. Nádej na liečbu cukrovky typu I. **2014**, Zem a vek; p.85

**Rázga F**, Uhelská L. Vedia ako vyliečiť cukrovku, TV JOJ; 24.10.2014  
(<http://velkenoviny.joj.sk/noviny-archiv/2014-10-24-velke-noviny-tv-joj.html>)

**Rázga F**, Uhelská L. Objevili lék na cukrovku?, TV Barrandov; 25.10.2014  
(<http://www.barrandov.tv/video/25849-nase-zpravy-25-10-2014>)

Lacik I, **Rázga F**, Uhelská L. Prelomová liečba cukrovky, RTVS; 30.10.2014  
(<http://www.rtvs.sk/televizia/program/detail/4173/spravy-rtvs/archiv?date=30.10.2014>)

**Rázga F**. Klub akčných hrdinov, **2015**  
(<http://www.dikymoc.sk/technologie/klub-akcnych-hrdinov/online-hlasovanie/filip-razga-phd/>)

**Rázga F**. Vesmír, ktorý hľadám. **2015**, Správy SAV 4.2015; p.6

**Rázga F**. Cukrovka. TV Markíza; 23.2.2017  
([https://www.youtube.com/watch?v=GKa0\\_SnOQFY&feature=youtu.be](https://www.youtube.com/watch?v=GKa0_SnOQFY&feature=youtu.be))

**Rázga F**. Diabetes. Informačná vojna; 20.1.2017  
(<http://www.infovojna.sk/archiv/informacna-vojna/2>)

**Rázga F**. Vyliečiteľná cukrovka?. Slobodný vysielateľ, V prvej línii; 10.3.2017  
(<https://slobodnyvysielac.sk/relacia/v-prvej-linii-35/?v=13dd621f2711>)